絞り込み

16532

広告

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.

著者 Denton CP , Ong VH , Xu S , Chen-Harris H , Modrusan Z , Lafyatis R , Khanna D , Jahreis A , Siegel J , Sornasse T
Ann Rheum Dis.2018 May 31 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (14view , 0users)

Full Text Sources

Medical

Miscellaneous

Skin fibrosis mediated by activated dermal fibroblasts is a hallmark of systemic sclerosis (SSc), especially in the subset of patients with diffuse disease. Transforming growth factor-beta (TGFβ) and interleukin-6 (IL-6) are key candidate mediators in SSc. Our aim was to elucidate the specific effect of IL-6 pathway blockade on the biology of SSc fibroblasts in vivo by using samples from a unique clinical experiment-the faSScinate study-in which patients with SSc were treated for 24 weeks with tocilizumab (TCZ), an IL-6 receptor-α inhibitor.
PMID: 29853453 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード